On February 19, 2019, Boya Biopharmaceutical Co., Ltd. announced that its controlling subsidiary, Guizhou Tian'an Pharmaceutical Co., Ltd. (hereinafter referred to as “Tian'an Pharmaceutical”), received the “Drug Supplementary Application Approval Document” issued by the State Food and Drug Administration for Metformin Hydrochloride Tablets (Specification: 0.25g). This drug has passed the consistency evaluation of quality and efficacy for generic drugs.

Guangzhou DiQi Pharmaceuticals Co., Ltd. (hereinafter referred to as “DiQi Pharmaceuticals Co., Ltd”) extends its heartfelt congratulations as the pharmaceutical research service provider for Tian'an Pharmaceutical's Metformin Hydrochloride Tablets project. In 2018, DiQi Pharmaceuticals Co., Ltd.'s pharmaceutical research services for Guangdong South China Pharmaceutical's Metformin Hydrochloride Tablets (0.25g) were the first to pass the consistency evaluation for generic drug quality and efficacy. Today, DiQi Pharmaceuticals Co., Ltd achieves another milestone, once again successfully assisting Tian'an Pharmaceutical in becoming the third enterprise to pass the consistency evaluation for this product specification!

We extend our gratitude to our partners for their continued trust and support of DiQi Pharmaceuticals Co., Ltd! We thank every member of the DiQi team for their hard work in pharmaceutical research and development!